There have been many recent advances in DEL technology with the promise of helping to deliver ever more efficacious and beneficial small molecule-based tools and therapies.
TORONTO (PRWEB) November 14, 2022
DNA-encoded small molecule libraries (DELs) created using combinatorial chemistry and synthetic oligonucleotides are being successfully applied to drug discovery projects across the pharmaceutical industry. There have been many recent advances in DEL technology with the promise of helping to deliver ever more efficacious and beneficial small molecule-based tools and therapies.
In this webinar, the featured speaker will review the use of state-of-the-art DEL technology to uncover compounds that modulate challenging therapeutic targets, including the following applications: Identification of hits to target in complex biological systems; Targeted protein degradation; Discovery of irreversible covalent binders
Identifying binders to nucleic acid targets; And enhanced hit identification of DEL screen output using machine learning.
Register for this webinar to learn about leading advances in DEL technology.
For more information, or to register for this event, visit Utilizing State-of-the-Art DEL Technology to Discover Compounds that Hit Challenging Therapeutic Targets.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Tel: +1 (416) 977-6555 x371